

# Doctor Care Anywhere

## Expanding footprint beyond the UK

Doctor Care Anywhere (ASX:DOC) is a UK based telehealth business which seeks to address the fragmentation prevalent in traditional healthcare systems by bringing together Primary and Secondary Care through its proprietary technology platform and its own clinicians. By providing online video and phone consultations through this modality, it offers private health insurers the opportunity to reduce costs (reducing unnecessary appointments) while at the same time improve patient experience and outcomes (increased speed from diagnosis to treatment). DOC listed on the ASX in December 2020, raising A\$102m at an issue price of A\$0.80/share, with \$47m representing a shareholder sell-down and \$65m new funds for expansion in the form of marketing and new vertical opportunities (mental health in particular). The group's current membership base represents circa 2.2m people (eligible lives), with DOC currently claiming 0.43m activated lives (signed up and providing personal details), mostly corporate employees who pay no out of pocket to use the service. COVID has been the major driver of telehealth adoption and recent consultation growth given the rolling lockdowns in the UK, with activated lives increasing from 145k in Q4CY19 to 433k in Q4CY20. Near-term growth centres around increasing activated lives across the existing membership base, increasing eligible lives through the Allianz partnership, growing the recently launched mental health offering and entering new regions. The group reported an EBITDA loss of £8.7m in CY20 (A\$15.5m), slightly better than prospectus forecasts.

### Business model

DOC has partnered with AXA (~80% of revenue) in the UK and Allianz in Europe to provide their customers with a telehealth service to diagnose and treat medical issues through video and phone consultations. DOC employs its own doctors, its panel consisting of ~160 GPs, 22 specialists and 9 triage professionals. In treating channel partner patients, DOC receives revenue from the number of GP/specialist consultations (employee utilisation) and rebates from referred diagnostics. The COGS of the business relate to the payment of the doctor panel for their services. Operating costs include software technology costs and corporate overheads. Longer-term DOC wants to replicate the UK model in APAC and across Europe, and better utilise/monetise patient data. Good progress has been made, with the business expanding into Ireland in October 2020 and its new partnership with Allianz in Europe.

### CY20 result commentary

DOC delivered impressive growth over CY20 with revenue +102%, consultations +306% and activated lives +199%. These numbers exceeded prospectus, as did the forecast EBITDA loss, coming in at £8.7m against a forecast £10.2m. DOC has activated 433k lives relative to an eligible lives membership base (the client base of its partners) of 2.2m.

### ANZ peers are bricks & mortar healthcare players

While DOC is a "telehealth" company, at the end of the day the business model employs health professionals and relies on the utilisation of these professionals to derive revenue and EBITDA. This is similar to Healix (ASX:HLS) in pathology, Virtus (ASX:VRT) & Monash IVF (ASX:MVF) in the IVF space. The company highlights US listed players Teladoc (NYSE:TDOC) and Amwell (NYSE:AMWL) as companies that provide the same services as DOC.

#### Historical earnings and ratios

Year end	Revenue (£\$m)	EBITDA Adj.* (£\$m)	NPAT Adj.* (£\$m)	NPAT Rep. (£\$m)	EPS Adj.*(c)	EPS Rep. (c)	EV/Sales (x)
06/18a	2.0	(6.1)	(7.0)	(7.0)	nm	nm	125.3
06/19a	5.7	(5.5)	(6.4)	(6.4)	nm	nm	43.9
06/20a	11.6	(8.7)	(8.7)	(31.3)	nm	nm	21.6

Source: Company data \*EBITDA and NPAT adj for one-time, non-cash items

## Healthcare services

12<sup>th</sup> March 2021

### Share details

ASX Code	DOC
Share price	\$1.00
Market Capitalisation	A\$318.5M
Shares on issue	318.5M
Net cash at 31/12/2020	A\$68.0M
Free float	55.45%

### Share performance (since listing)



### Upside Case

- Better utilisation of their doctor panel
- Execution of European expansion
- Rollout of additional clinical pathways

### Downside Case

- Patients revert to "face to face" consultations post COVID, reducing utilisation
- Multiples of tech and more specifically telehealth stocks contract
- New technology

### Catalysts/upcoming events

- Q1 FY21 trading update (April 2021)
- Q2 FY21 trading update (July 2021)

### Comparable companies (Aust/NZ)

Virtus (ASX:VRT), Healix (ASX:HLS), Monash IVF (ASX: MVF)

### Top 5 shareholders

Caraini Holdings	13.9%
Caledonia Invest	9.4%
Bhikhu Patel	8.2%
BGF Investment	6.8%
Pie Funds	5.0%

### Company contacts

Investor Relations +61 401 278 906  
(Roger Newby)

### RaaS Advisory contacts

John Burgess +61 410 439 723  
John.burgess@raasgroup.com



# FINANCIAL SERVICES GUIDE

**RaaS Advisory Pty Ltd**

**ABN 99 614 783 363**

**Corporate Authorised Representative, number 1248415**

**of**

**BR SECURITIES AUSTRALIA PTY LTD**

**ABN 92 168 734 530**

**AFSL 456663**

**Effective Date: 26<sup>th</sup> November 2018**



### **About Us**

BR Securities Australia Pty Ltd (BR) is the holder of Australian Financial Services License ("AFSL") number 456663. RaaS Advisory Pty Ltd (RaaS) is an Authorised Representative (number 1248415) of BR.

This Financial Service Guide (FSG) is designed to assist you in deciding whether to use RaaS's services and includes such things as

- who we are
- our services
- how we transact with you
- how we are paid, and
- complaint processes

Contact Details, BR and RaaS

BR Head Office: Level 14, 344 Queen Street, Brisbane, QLD, 4000

RaaS. 20 Halls Road Arcadia, NSW 2159

P: +61 414 354712

E: [finola.burke@raasgroup.com](mailto:finola.burke@raasgroup.com)

RaaS is the entity providing the authorised AFSL services to you as a retail or wholesale client.

**What Financial Services are we authorised to provide?** RaaS is authorised to

- provide general advice to retail and wholesale clients in relation to
  - Securities
- deal on behalf of retail and wholesale clients in relation to
  - Securities

The distribution of this FSG by RaaS is authorized by BR.

### **Our general advice service**

Please note that any advice given by RaaS is general advice, as the information or advice given will not take into account your particular objectives, financial situation or needs. You should, before acting on the advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Prospectus, Product Disclosure Statement or like instrument. As we only provide general advice we will not be providing a Statement of Advice. We will provide you with recommendations on securities

### **Our dealing service**

RaaS can arrange for you to invest in securities issued under a prospectus by firstly sending you the offer document and then assisting you fill out the application form if needed.

### **How are we paid?**

RaaS earns fees for producing research reports. Sometimes these fees are from companies for producing research reports and/or a financial model. When the fee is derived from a company, this is clearly highlighted on the front page of the report and in the disclaimers and disclosures section of the report.

We may also receive a fee for our dealing service, from the company issuing the securities.

### **Associations and Relationships**

BR, RaaS, its directors and related parties have no associations or relationships with any product issuers other than when advising retail clients to invest in managed funds when the managers of these funds may also be clients of BR. RaaS's representatives may from time to time deal in or otherwise have a financial interest in financial products recommended to you but any material ownership will be disclosed to you when relevant advice is provided.

### **Complaints**

If you have a complaint about our service you should contact your representative and tell them about your complaint. The representative will follow BR's internal dispute resolution policy, which includes sending you a copy of the policy when required to. If you aren't satisfied with an outcome, you may contact AFCA, see below. BR is a member of the Australian Financial Complaints Authority (AFCA). AFCA provide fair and independent financial services complaint resolution that is free to consumers.

Website: [www.afca.org.au](http://www.afca.org.au); Email: [info@afca.org.au](mailto:info@afca.org.au); Telephone: 1800931678 (free call)

In writing to: Australian Financial Complaints Authority, GPO Box 3, Melbourne, VIC, 3001.

### **Professional Indemnity Insurance**

BR has in place Professional Indemnity Insurance which satisfies the requirements for compensation under s912B of the Corporations Act and that covers our authorized representatives.

## DISCLAIMERS and DISCLOSURES

This report has been prepared and issued by RaaS Advisory Pty Ltd. This research is issued in Australia by RaaS Advisory and any access to it should be read in conjunction with the Financial Services Guide on the preceding two pages. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable. Opinions contained in this report represent those of the principals of RaaS Advisory at the time of publication. RaaS Advisory provides this financial advice as an honest and reasonable opinion held at a point in time about an investment's risk profile and merit and the information is provided by the RaaS Advisory in good faith. The views of the adviser(s) do not necessarily reflect the views of the AFS Licensee. RaaS Advisory has no obligation to update the opinion unless RaaS Advisory is currently contracted to provide such an updated opinion. RaaS Advisory does not warrant the accuracy of any information it sources from others. All statements as to future matters are not guaranteed to be accurate and any statements as to past performance do not represent future performance. RaaS Advisory's principals, employees and associates may hold shares in companies that are covered and, if so, this will be clearly stated on the front page of each report.

Assessment of risk can be subjective. Portfolios of equity investments need to be well diversified and the risk appropriate for the investor. Equity investments in listed or unlisted companies yet to achieve a profit or with an equity value less than \$50 million should collectively be a small component of a balanced portfolio, with smaller individual investment sizes than otherwise.

The science of climate change is common knowledge and its impacts may damage the global economy. Mitigating climate change may also disrupt the global economy. Investors need to make their own assessments and we disclaim any liability for the impact of either climate change or mitigating strategies on any investment we recommend.

Investors are responsible for their own investment decisions, unless a contract stipulates otherwise. RaaS Advisory does not stand behind the capital value or performance of any investment. Subject to any terms implied by law and which cannot be excluded, RaaS Advisory shall not be liable for any errors, omissions, defects or misrepresentations in the information (including by reasons of negligence, negligent misstatement or otherwise) or for any loss or damage (whether direct or indirect) suffered by persons who use or rely on the information. If any law prohibits the exclusion of such liability, RaaS Advisory limits its liability to the re-supply of the Information, provided that such limitation is permitted by law and is fair and reasonable. Copyright 2021 RaaS Advisory Pty Ltd (A.B.N. 99 614 783 363). All rights reserved.